[HTML][HTML] Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
J Tan, S Cang, Y Ma, RL Petrillo, D Liu - Journal of hematology & oncology, 2010 - Springer
Histone deacetylases (HDACs) can regulate expression of tumor suppressor genes and
activities of transcriptional factors involved in both cancer initiation and progression through …
activities of transcriptional factors involved in both cancer initiation and progression through …
[HTML][HTML] Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
S Wang, S Cang, D Liu - Journal of hematology & oncology, 2016 - Springer
The tyrosine kinase inhibitors (TKI) against epidermal growth factor receptor (EGFR) are
widely used in patients with non-small cell lung cancer (NSCLC). However, EGFR T790M …
widely used in patients with non-small cell lung cancer (NSCLC). However, EGFR T790M …
[HTML][HTML] ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
S Cang, C Iragavarapu, J Savooji, Y Song… - Journal of hematology & …, 2015 - Springer
With the advent of new agents targeting CD20, Bruton’s tyrosine kinase, and phosphoinositol-3
kinase for chronic lymphoid leukemia (CLL), more treatment options exist than ever …
kinase for chronic lymphoid leukemia (CLL), more treatment options exist than ever …
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 …
Z Ren, J Xu, Y Bai, A Xu, S Cang, C Du, Q Li… - The Lancet …, 2021 - thelancet.com
Background China has a high burden of hepatocellular carcinoma, and hepatitis B virus (HBV)
infection is the main causative factor. Patients with hepatocellular carcinoma have a poor …
infection is the main causative factor. Patients with hepatocellular carcinoma have a poor …
[PDF][PDF] Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial
…, T Dai, T Mao, L Chen, Z Guo, B Liu, H Pan, S Cang… - Cancer cell, 2022 - cell.com
Platinum-based chemotherapy is the standard first-line treatment for advanced esophageal
squamous cell carcinoma (ESCC). In this phase 3 study (ClinicalTrial.gov: NCT03829969), …
squamous cell carcinoma (ESCC). In this phase 3 study (ClinicalTrial.gov: NCT03829969), …
[HTML][HTML] Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized …
Y Yang, Z Wang, J Fang, Q Yu, B Han, S Cang… - Journal of Thoracic …, 2020 - Elsevier
Introduction Sintilimab, an anti–programmed death 1 antibody, plus pemetrexed and
platinum had revealed promising efficacy for nonsquamous NSCLC in a phase 1b study. We …
platinum had revealed promising efficacy for nonsquamous NSCLC in a phase 1b study. We …
[HTML][HTML] Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: results from a randomized, double-blind, phase …
…, L Liu, G Chen, L Zhang, D Huang, S Cang… - Journal of Thoracic …, 2021 - Elsevier
Introduction The standard chemotherapy for squamous NSCLC (sqNSCLC) includes platinum
plus gemcitabine. Sintilimab, an anti–programmed cell death protein 1 antibody, plus …
plus gemcitabine. Sintilimab, an anti–programmed cell death protein 1 antibody, plus …
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on …
…, B Li, Y Pan, X Li, F Ye, A Liu, K Wang, S Cang… - The Lancet …, 2022 - thelancet.com
Background VEGF inhibitors can enhance the efficacy of immunotherapy. However, despite
high initial response rates, almost all patients eventually develop treatment resistance to …
high initial response rates, almost all patients eventually develop treatment resistance to …
Exosomal miR-4443 promotes cisplatin resistance in non-small cell lung carcinoma by regulating FSP1 m6A modification-mediated ferroptosis
Z Song, G Jia, P Ma, S Cang - Life sciences, 2021 - Elsevier
Aims Exosomal transfer of miRNAs affects recipient cell proliferation and chemoresistance.
Here, we aimed to investigate the role of exosomal miRNAs in controlling cisplatin resistance …
Here, we aimed to investigate the role of exosomal miRNAs in controlling cisplatin resistance …
[HTML][HTML] Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-Sq): a phase 3 trial
…, Y Geng, C Xing, D Lv, Y Zhang, J Yu, S Cang… - Journal of Thoracic …, 2022 - Elsevier
Introduction Camrelizumab, a humanized immunoglobulin G4-κ monoclonal antibody against
programmed cell death protein 1, has exhibited antitumor activity and tolerability across …
programmed cell death protein 1, has exhibited antitumor activity and tolerability across …